On February 1, Vertex’s Board of Directors approved a new share repurchase program, authorizing the repurchase of up to $3.0 billion of our common stock.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on VRTX:
- Vertex options imply 3.7% move in share price post-earnings
- Vertex keeps cystic fibrosis drug out of developing countries, NY Times reports
- Vertex Pharmaceuticals price target raised to $296 from $293 at Piper Sandler
- Vertex Pharmaceuticals initiated with a Hold at Canaccord
- SVB Securities upgrades Vertex to Outperform, raises price target to $374